Indian Journal of Endocrinology and Metabolism

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 24  |  Issue : 5  |  Page : 402--405

Health-related quality of life in acromegaly patients: Results from generic and disease-specific questionnaires


Bruno de A. Oliveira1, Bruna Araújo2, Tainá M dos Santos2, Bárbara R Ongaratti1, Carolina G. S Leães Rech2, Nelson P Ferreira2, Julia F S. Pereira-Lima3, Miriam da C. Oliveira3 
1 Programa de Pos-Graduacao em Patologia, Universidade Federal de Ciencias da Saude de Porto Alegre (UFCSPA), Porto Alegre, RS, Brasil
2 Centro de Neuroendocrinologia, Complexo Hospitalar Santa Casa, UFCSPA, Porto Alegre, RS, Brasil
3 Programa de Pos-Graduacao em Patologia, Universidade Federal de Ciencias da Saude de Porto Alegre (UFCSPA); Centro de Neuroendocrinologia, Complexo Hospitalar Santa Casa, UFCSPA, Porto Alegre, RS, Brasil

Correspondence Address:
Miriam da C. Oliveira
Rua Sarmento Leite, 245; Sala 402, Predio 1/90050-170 - Porto Alegre, RS
Brasil

Introduction: Acromegaly is associated with high morbidity, but still controversial impact on the overall quality of life (QoL). Material and Methods: We evaluated QoL using a generic (SF-36) and a disease-specific questionnaire (AcroQoL) in an acromegalic cohort. Results: Sixty-nine patients answered the questionnaires and had their records reviewed. In the SF-36 questionnaire, except for the Social Aspects domain, all others revealed a reduction in scores from 9.7 to 38.9%, when compared to the non-acromegalics. The cure was positively correlated with mental health (P = 0.023) and drug control was correlated with mental health (P = 0.023) and functional capacity (P = 0.013). In the AcroQoL questionnaire, the mean scores ranged from 54.7% to 72.8%. The use of antidepressants correlated with lower scores on the total AcroQoL (P = 0.039) and physical complaints (P = 0.003). The growth hormone value at diagnosis showed an inverse correlation with the total AcroQoL score (P = 0.014), Appearance Issues subscale (P = 0.081), and Personal Relations (P = 0.002). IGF-1 values at diagnosis and at the last visit showed no statistical correlation with any of the questionnaires. Conclusion: The finding of a reduction in QoL scores with both SF-36 and AcroQoL allows us to suggest this evaluation as part of the initial assessment and follow-up in acromegaly, to act globally on the individual's health condition.


How to cite this article:
A. Oliveira Bd, Araújo B, dos Santos TM, Ongaratti BR, Leães Rech CG, Ferreira NP, S. Pereira-Lima JF, C. Oliveira Md. Health-related quality of life in acromegaly patients: Results from generic and disease-specific questionnaires.Indian J Endocr Metab 2020;24:402-405


How to cite this URL:
A. Oliveira Bd, Araújo B, dos Santos TM, Ongaratti BR, Leães Rech CG, Ferreira NP, S. Pereira-Lima JF, C. Oliveira Md. Health-related quality of life in acromegaly patients: Results from generic and disease-specific questionnaires. Indian J Endocr Metab [serial online] 2020 [cited 2020 Nov 26 ];24:402-405
Available from: https://www.ijem.in/article.asp?issn=2230-8210;year=2020;volume=24;issue=5;spage=402;epage=405;aulast=A.;type=0